Vimentin is a type III intermediate filament protein predominantly expressed in mesenchymal and non-epithelial cells, where it maintains cytoskeletal integrity and regulates organelle positioning, cell adhesion, migration, and mechanotransduction. In cancer, vimentin is a defining marker of epithelial-to-mesenchymal transition (EMT) and plays a central role in metastasis, therapeutic resistance, and tumor progression. Elevated vimentin expression is associated with poor prognosis in multiple malignancies, including breast, lung, and colorectal cancers. Beyond its structural functions, extracellular vimentin actively modulates immune responses and tumor microenvironment dynamics, further underscoring its value as a biomarker and therapeutic target. Catalina’s rigorously validated vimentin antibodies are reliable tools for investigating cytoskeletal remodeling, EMT biology, cancer progression, and translational pathology.